Phase 2 Myeloma Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are willing and able to give their own consent, sign a consent form, and follow the trial schedule, including visits, treatments, and tests
• People who have been clinically diagnosed with a blood cancer that has come back or has not responded to previous treatment
• People aged 18 or older, of any gender
• People with a general health and activity level rated 0 to 2 on a standard medical scale (meaning they are able to care for themselves and are not completely inactive — confirm with trial site)
• People whose doctors expect them to survive for more than 3 months from the time of signing the consent form
• People whose haemoglobin (a measure of red blood cell health) is at or above a certain level (blood transfusions to reach this level are allowed)
• People whose kidney function, liver function, and heart and lung function meet specific medical thresholds, including heart pumping strength of at least 50%, blood oxygen above 90%, and kidney and liver markers within acceptable ranges (confirm exact values with trial site)
• People who agree to use contraception during the trial and for six months after, if there is any possibility of pregnancy, and who agree to notify the trial team immediately if pregnancy occurs or is suspected

For the Lymphoma group specifically, people may be eligible if they have:

• A confirmed diagnosis of B-cell lymphoma where the cancer cells test positive for one or more specific markers (CD19, CD20, CD22, or BAFF), covering both slower-growing and faster-growing types
• B-cell lymphoma that has relapsed or not responded to standard treatment, including having received prior treatment with an anti-CD20 antibody and a standard chemotherapy combination (specific relapse/refractory criteria apply — confirm with trial site)
• A confirmed diagnosis of CD7-positive T-cell lymphoma that has relapsed after at least two prior treatment courses, or has not achieved full remission with at least two prior treatments

For the Acute Lymphoblastic Leukaemia (ALL) group specifically, people may be eligible if they have:

• A confirmed diagnosis of B-cell ALL where cancer cells test positive for one or more specific markers (CD19, CD20, CD22, or BAFF), and the disease has relapsed or not responded to treatment (specific criteria apply — confirm with trial site)
• A confirmed diagnosis of CD7-positive T-cell ALL that has not responded to standard treatment, relapsed within 12 months of first remission, or relapsed two or more times

For the Multiple Myeloma group specifically, people may be eligible if they have:

• Myeloma cells that test positive for at least one of the following markers: BCMA, CD19, or GPRC5D
• Previously received at least one prior treatment course that included specific drug types (proteasome inhibitors and/or immunomodulatory drugs), or whose disease has not responded to those drug types

For the Myeloid Tumour group (including AML and MDS) specifically, people may be eligible if they have:

• Tumour cells that test positive for at least one of the following markers: CD7, CD19, or CD47
• Disease that has relapsed after achieving remission with second-line or later treatment, or disease that has not achieved remission after at least two cycles of standard chemotherapy

Who may not be able to join:

• People with a history of serious heart failure where heart pumping strength has been below 50%
• People with a history of serious lung disease that significantly affects lung function
• People who also have another cancer that is currently progressing
• People who have a severe infection that cannot be effectively controlled
• People with a severe autoimmune disease or a condition where the immune system does not work properly from birth
• People with active hepatitis B or hepatitis C, where the virus is currently detectable in the blood
• People with HIV infection, AIDS, or syphilis
• People with a history of severe allergic reactions to biological medicines, including antibiotics
• People who have had an allogeneic stem cell transplant (from a donor) and still have acute graft-versus-host disease one month after stopping immunosuppressant medications
• People with other serious physical or mental health conditions, or abnormal test results, that could increase the risks of the trial or affect the results — including anyone the trial doctor considers unsuitable for participation

Important: Always verify eligibility with the trial site directly before applying.